Can-Fite BioPharma Ltd. (CANF) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Can-Fite BioPharma Ltd. (CANF) closed at USD 1.93 on 2026-10-14, a change of -79 % over the past year, with a market capitalization of USD 5.61M.
Can-Fite BioPharma Ltd. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 1.93 |
| 2026-10-13 | 1.95 |
| 2026-10-12 | 1.95 |
| 2026-10-09 | 1.90 |
| 2026-10-08 | 2.00 |
| 2026-10-07 | 2.10 |
| 2026-10-06 | 2.14 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Can-Fite BioPharma Ltd. key figures
- Previous close
- USD 1.93 (2026-10-14)
- 1-year change
- -79 %
- Market cap
- USD 5.61M
- Enterprise value
- USD -3.03M
- P/E ratio (trailing)
- -0.15
- P/E ratio (forward)
- -2.03
- EPS (trailing)
- -12.55
- EPS (forward)
- -0.91
- PEG ratio
- n/a
- Price to book
- 0.82
- Revenue growth
- 0 %
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 0.06
- Employees
- 5
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Can-Fite BioPharma Ltd. and compare it with other stocks.
Analyze CANFAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Can-Fite BioPharma Ltd. shares.